Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global venous leg ulcer (VLU) treatment market was valued at US$ 3.8 billion in 2021 and is expected to register a revenue CAGR of 5.8% to reach US$ 6.31 billion by 2030. 

Venous Leg Ulcer (VLU) Treatment Market Fundamentals

Ulcers are open sores on the skin, usually visible in the legs. Abnormality with the blood circulation in the legs results in leg ulcers known as venous ulcers. Veins have small valves that keep blood moving throughout the body. To transport blood back to the heart against the pull of gravity, these valves quickly open and close. Damage to the valves inside the leg veins typically leads to venous ulcers.

Sustained venous hypertension is the term used when the blood pressure in the veins of the legs does not decrease while walking. Ankle ulcers develop due to elevated blood pressure. Venous ulcers most frequently develop in the ankles. Other problems with leg veins, such as varicose veins, chronic venous insufficiency, and chronic venous insufficiency, may also cause venous ulcers. Varicose veins are enlarged, bulging veins in the legs. They develop when vein valves in the legs do not work properly, leading to blood pooling in the lower leg. Similar to varicose veins, chronic venous insufficiency develops when the leg veins are unable to pump blood back up to the heart. The legs then enlarge due to blood pooling in the lower legs. Extreme inflammation may result from poor blood supply in the legs. The pressure from this excessive swelling may cause venous ulcers to develop on the skin. Other medical conditions, such as diabetes, deep vein thrombosis, obesity, and paralysis, can also increase the risk of leg and foot ulcers.

Early stages of venous ulcers are frequently disregarded or incorrectly diagnosed. Venous leg ulcers often start as rashes or red, inflamed skin, and they eventually turn into open wounds. Venous leg ulcers can be spotted by paying close attention to how your legs look. Some venous ulcers, which are also painful, may produce a small quantity of discharge. One of the initial indications of a venous ulcer is cracked, dry, or reddish skin. Typically, a physical examination is required to diagnose a venous ulcer. The healthcare professional may inquire about the patient’s medical history to find out about any diseases that may have contributed to the ulcer. The severity of the ulcer is determined through testing. The effectiveness of venous ulcer treatments must be monitored often by testing. Ankle-brachial index and imaging studies, such as CT scans, are some of the diagnostic tests used to determine venous leg ulcers. Mild cases of venous leg ulcers can be treated with simple at-home remedies. Additional treatments could be necessary for severe venous ulcers or the ones not responding to regular medicines. Some other treatments include growth factor therapy, hyperbaric oxygen therapy, and Skin graft. 

[968759]

Venous Leg Ulcer (VLU) Treatment Market Dynamics 

Rising prevalence of peripheral vascular disease (PVD), deep vein thrombosis (DVT), and hypertension is increasing the prevalence of venous leg ulcers, which in turn, is driving the revenue growth of the venous leg ulcer (VLU) treatment market. Rising adoption of a sedentary lifestyle and smoking and increasing obese population play a significant role in the revenue growth of the venous leg ulcer (VLU) treatment market.

Escalating number of diabetes cases globally increases the patient pool for venous leg ulcers, thus expanding the demand for venous leg ulcer treatment. Rising geriatric population and increased hip and knee replacement are increasing the chances of venous leg ulcers, propelling the revenue growth of the venous leg ulcer (VLU) treatment market. Moreover, rising adoption of advancements in the treatment, such as innovative dressings and compression therapy, is fueling the venous leg ulcer (VLU) treatment market revenue growth. Expanding R&D and development of novel treatments for venous leg ulcers, such as stem cell therapy, growth factor therapy, and hyperbaric oxygen therapy, is also expected to boost the revenue expansion of the venous leg ulcer (VLU) treatment market.

However, high cost associated with the treatment products for venous leg ulcers is likely to restrict the revenue growth in the venous leg ulcer (VLU) treatment market. Moreover, lack of awareness in developing countries is hampering the market's revenue growth. 

Venous Leg Ulcer (VLU) Treatment Market Ecosystem

The global venous leg ulcer (VLU) treatment market is analyzed from four perspectives: product, stage of disease, end-user, and region. 

Venous Leg Ulcer (VLU) Treatment Market by Product

Based on the product, the global venous leg ulcer (VLU) treatment market is segmented into advanced wound dressing, compression therapy, negative pressure wound therapy, skin grafts, substitutes, medications, and others. 

The compression therapy segment dominates the venous leg ulcer (VLU) treatment market. The revenue growth of the segment is attributed to the introduction of enhanced compression bandages and stocking for the management of venous leg ulcers. Compression bandages are designed to squeeze the leg to encourage blood to flow upwards toward the heart. Moreover, increasing awareness about the usage of compression bandages and advancements in the therapy boost revenue growth in the segment. 

Venous Leg Ulcer (VLU) Treatment Market by Stage of Disease 

[96856]

Based on the stage of the disease, the global venous leg ulcer (VLU) treatment market is segmented into stage I, stage II, stage III, and stage IV.

The stage III segment accounts for the largest revenue share of the global market. The damaged skin area starts to perish at this stage, which is the underlying cause of the ulcer; thus, most of the time, venous leg ulcers are detected at this stage. Moreover, venous ulcers may occasionally start to heal and reopen once again in this stage. This, in turn, boosts the demand for venous leg ulcer treatment. 

Venous Leg Ulcer (VLU) Treatment Market by End-user

Based on the end-user, the global venous leg ulcer (VLU) treatment market is segmented into hospitals & clinics, home care settings, and others.

The hospitals & clinics segment accounts for a significant revenue share of the venous leg ulcer (VLU) treatment market. The treatment of venous leg ulcers requires continuous supervision, and treatment such as compression therapy requires skilled professionals who are available in hospitals. Moreover, hospitals have much-developed infrastructures and equipment. These factors are propelling the revenue growth in the segment. 

Venous Leg Ulcer (VLU) Treatment Market by Region

Based on the region, the global venous leg ulcer (VLU) treatment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.

North America dominates the global venous leg ulcer (VLU) treatment market, followed by Europe and Asia Pacific. Rise in the prevalence of diabetes, deep vein thrombosis (DVT), and hypertension is increasing the patient pool for venous leg ulcers in the region, increasing the demand for venous leg ulcer treatment. The sedentary lifestyle, increased tobacco consumption, and growing obese population in the region are also boosting regional revenue growth. Moreover, rise in awareness about venous leg ulcers, well-developed healthcare infrastructure, and presence of major players in the region are expected to fuel regional revenue growth. 

Venous Leg Ulcer (VLU) Treatment Market Competitive Landscape

The prominent players operating in the venous leg ulcer (VLU) treatment market are: 

• Integra Lifesciences
• AngioDynamics Inc. 
• Sigvaris Group
• Smith & Nephew Plc
• Coloplast Corp.
• URGO Group
• 3M Company
• Paul Hartmann AG
• Cardinal Health Inc.
• KCI Licensing, Inc.

Venous Leg Ulcer (VLU) Treatment Market Strategic Development/s 

• In January 2023, MiMedx Group, Inc. entered into an exclusive distribution agreement with GUNZE MEDICAL LIMITED for the sales of EPIFIX in Japan. EPIFIX is a PURION® processed placental tissue allograft that supports the healing cascade by providing a semi-permeable, protective barrier over wounds.

Frequently Asked Questions About This Report